Various graft vs. host diseases (GvHD) in rodents can be prevented and treated by malononitrilamides (MNAs)

被引：0
|
作者：
H. U. Schorlemmer
R. Kurrle
R. R. Bartlett
机构：
[1] Research Laboratories Hoechst Marion Roussell (HMR),
[2] TA Rheumatology/Immunology,undefined
[3] c/o Behringwerke AG,undefined
[4] P.O. Box 1140,undefined
[5] D-35001 Marburg,undefined
[6] Germany,undefined
[7] Fax +49 6421 39 46 63,undefined
[8] Werk Kalle-Albert,undefined
[9] D-65174 Wiesbaden,undefined
[10] Germany,undefined
来源：
Inflammation Research | 1997年 / 46卷 / Suppl 2期
关键词：
Host Disease;
D O I：
10.1007/s000110050160
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：165 / 166
页数：1
相关论文
共 50 条
  • [21] Hypofibrinogenemia and an infection-masking effect of tocilizumab in patients treated due to graft vs. host disease or cytokine release syndrome
    Sadowska-Klasa, Alicja
    Piekarska, Agnieszka
    Mensah-Glanowska, Patrycja
    Bieniaszewska, Maria
    Zaucha, Jan Maciej
    BONE MARROW TRANSPLANTATION, 2019, 54 : 316 - 317
  • [22] Allogeneic Cord Blood Regulatory T Cells Can Prevent Graft Vs. Host Disease and Preserve Graft Vs Leukemia Effect: Update on Phase I/II Clinical Trial
    Zeng, Ke
    Ma, Hongbing
    Popat, Uday
    Nieto, Yago
    Ciurea, Stefan O.
    Olson, Amanda L.
    Lyu, Mi-Ae
    Huang, Meixian
    Nishimoto, Mitsutaka
    Qazilbash, Muzaffar H.
    Ramos, Jennifer D.
    Shpall, Elizabeth J.
    Champlin, Richard E.
    Parmar, Simrit
    Andersson, Borje S.
    BLOOD, 2019, 134
  • [23] Is timing of anti-thymocyte globulin (ATG) - Pre and post-hematopoietic stem cell transplants (HSCT) - Relevant for graft vs. host disease (GvHD)?
    Dominietto, A
    Van Lint, MT
    Gualandi, F
    Lamparelli, T
    Occhini, D
    di Grazia, C
    Bregante, S
    Raiola, AM
    Ibatici, A
    Frassoni, F
    Bacigalupo, A
    BLOOD, 2003, 102 (11) : 242A - 242A
  • [24] NFAT1 Regulatory Mechanisms in UCB-Derived CD4+ T-cells: Implications for Graft vs. Host Disease (GVHD)
    Weitzel, Richard Patrick
    Lesniewski, Mathew
    Laughlin, Mary J.
    FASEB JOURNAL, 2008, 22
  • [25] Organ disfunction after the preparative regimen predicts for severe graft vs. host disease (GVHD) in patients undergoing allogeneic blood stem cell transplantation.
    Haire, WD
    Lynch, JC
    Pavletic, SZ
    Schneider, J
    Tarantolo, S
    BLOOD, 1999, 94 (10) : 157A - 157A
  • [26] Chronic graft vs. host disease (GVHD), bronchiolytis obliterans (BO) and bilateral lung trasplantation after allogenic stem cell transplantation (ASCT) for aplastic anemia.
    Riera, L
    Dupont, J
    Valentini, R
    Solimano, J
    Fernandez, J
    Cacchione, R
    Riveros, D
    BLOOD, 2003, 102 (11) : 457B - 457B
  • [27] INTERCEPT platelets treated with Helinx® technology to inactivate T-cells prevented transfusion-associated graft-versus-host disease (TA-GVHD):: results of 3 clinical trials
    Conlan, M
    Lin, JS
    Flament, J
    Lin, L
    Corash, L
    BONE MARROW TRANSPLANTATION, 2003, 31 : S222 - S222
  • [28] TWICE DAILY INTRAVENOUS TACROLIMUS (FK-506) IS A SAFE AND EFFECTIVE GRAFT VS. HOST DISEASE (GVHD) PROPHYLAXIS FOR PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL (HSCT) RECIPIENTS
    Skeens, M. A.
    Pai, V
    Garee, A.
    Bajwa, R.
    Gross, T.
    Termuhlen, A.
    Soni, S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (02) : S328 - S328
  • [29] NFAT1 in adult and cord blood-derived human CD4+ T-cells:: Regulatory implications for graft vs. host disease (GVHD).
    Weitzel, R. P.
    Lesnewski, M. L.
    Huang, Y.
    Fanning, L. R.
    Laughlin, Mary
    BLOOD, 2006, 108 (11) : 903A - 903A
  • [30] In vitro T cell receptor Vβ repertoire analysis can identify which T cells mediate graft vs. leukemia (GVL) and graft vs. host (GVH) responses after HLA-matched sibling bone marrow transplantation.
    Epperson, DE
    Margolis, DA
    McOlash, L
    Janczak, T
    Barrett, AJ
    BLOOD, 1999, 94 (10) : 325A - 325A
12345